Lupron Depot (leuprolide acetate) cost per injection and what the patient owes

$479.7472 per mg is Part B's ASP+6% rate for Q4 2026, and J1950 is billed per 3.75 mg, not per mg and not per syringe. Once the $283 Part B deductible is met, the patient owes the remaining coinsurance on the drug (18.5%) and its administration (20%), with no annual out-of-pocket maximum to cap it. Full explanation: How Medicare Part B drug cost sharing works →

One 3.75 mg unit is $1,799.05. The 1-month kit is 1 unit; the 3-month, 11.25 mg kit is 3 units on the same claim line. For the 1-month kit, Medicare allows $1,799.05 for the drug plus $15.36 for the 96372 injection code, a total of $1,814.41, and the patient's share is $335.98 (18.5% coinsurance on the drug, 20% on the administration). For the 11.25 mg kit, the same $479.7472-per-mg rate is billed as 3 units, so the drug allowance is $5,397.16; with the $15.36 injection code, the claim totals $5,412.52. The rate per unit is identical either way — the kit changes only the quantity on the line, not the price per 3.75 mg.

Six 1-month kits, the labeled maximum for an initial endometriosis course, bring the drug and administration to $10,886.47 before the 2% sequester, across a 6-month course, never a year of treatment. Retreatment beyond that initial course is labeled only with norethindrone acetate add-back and is capped at 12 months lifetime. The fibroid course is shorter: up to 3 monthly kits, or a single 11.25 mg kit, given before surgery. We don't total that course here, because the preoperative timeline, not a fixed dose count, decides how many kits are billed.

AbbVie sells leuprolide acetate under three different codes, and only J1950's gynecology kits are what this page prices. The same brand's prostate-cancer strengths (7.5, 22.5, 30 and 45 mg) bill J9217, priced far lower per mg, and Lupron Depot-Ped for central precocious puberty bills J1950 too but isn't part of this page's coverage corpus. A claim coded J9217 against an endometriosis or fibroid diagnosis, or J1950 against a prostate-cancer diagnosis, is a mismatch a payer will catch.

Zoladex (goserelin acetate implant, J9202) has no ASP+6% entry for Q4 2026 and is omitted from this table. Camcevi bills J1952 and Eligard bills J9217; neither carries a rate that prices directly against J1950's per-3.75-mg unit.

For the reference patient (3.75 mg, 1 unit, drug plus the 96372 administration code), Medicare allows $1,814.41, and the Part B coinsurance on that is $335.98. Plans A, B, C, D, F, G, M and N cover that coinsurance in full, so those patients owe nothing per kit once the $283 deductible is met. Plans K and L do not, and because a treatment course starts and stops within the plan year rather than running indefinitely, which kit lands before the deductible is met can matter more here than it does for a drug taken on and on. The kit that lands before the deductible is met costs a Plan K patient $424.81; the kit after it costs $168.00. A 6-month course crosses that deductible line only once, in whichever kit falls in the month the Part B deductible resets. See what each Medigap plan (A–N) owes on this claim →

Only the letters that leave this patient a balance are listed. The full A–N grid, the high-deductible variants, Plan N’s office-visit carve-out and the MACRA restriction on Plans C and F are at Medigap Plans A–N.

Payers negotiate their own rate for J1950 rather than following ASP+6%. Our corpus holds published rates from 37 payers, including Aetna, UnitedHealthcare, Cigna, Anthem, Regence, Premera and Kaiser, and all 37 carry a rate for this code. Aetna’s all-states median is $2,046 per 3.75 mg unit, well above Medicare’s $1,799.05 ASP+6% rate: the 1-month kit prices at $2,046 before benefits, and the 3-month, 11.25 mg kit at $6,138.00. What the patient owes then depends on their specific benefits. Full explanation: How commercial drug reimbursement works →

Medicare's ASP+6% rate for the drug itself doesn't change by site of service. The gynecology kits are a short in-office intramuscular injection, not an infusion, so nearly every claim bills under the physician fee schedule's injection code (96372) rather than a hospital-outpatient facility fee. Our coverage corpus tags site of care in only 2 of the 20 leuprolide acetate policies: a BCBS South Carolina rule that ties the fibroid indication to preoperative timing rather than a facility requirement, and a Cigna line that names the code and formulation rather than restricting where it's given. Neither reads as a blanket in-office mandate. Our data doesn't carry a Lupron Depot-specific hospital-outpatient facility rate, so this estimator only prices the office/physician-fee-schedule path.

Place of service (POS) is what drives that rate split. POS 11 (office) prices the admin code at the non-facility physician fee schedule rate, which is the path this estimator prices. A site-of-care rule that sends the same claim to POS 19 (off-campus hospital outpatient), POS 22 (hospital outpatient) or POS 24 (ambulatory surgical center) moves the admin code to the facility rate instead — a different number for the same CPT code. Confirm the POS on the claim before comparing an admin-fee estimate against what a payer actually paid.

The rate climbed every quarter for two years, then dropped in Q4 2026:

The Q3 2026 rate ($1,841.26) applied to a 1-month kit is $42.21 more than the current Q4 2026 rate ($1,799.05), a figure that still shows up on outdated pages. That gap widens to $126.63 across a 3-month kit's 3 units. Use the quarter that is actually in effect for the claim's date of service.

On a commercial plan, AbbVie's card can take the patient's cost for the drug down to $10 per kit, up to $3,600 a year: on the 1-month kit example above, that is the difference between the $332.91 drug coinsurance the estimator shows and a $10 copay. It does not touch the administration line, and it excludes Medicare, Medicaid and other federal program patients.

For uninsured patients, myAbbVie Assist provides the drug at no cost, for households at or below 400% of the federal poverty level. On Medicare, no manufacturer program touches the coinsurance, and none of the five foundation funds in our programs corpus for this drug reach these indications: Good Days, HealthWell's prostate, breast and head-and-neck cancer funds, and PAN's prostate fund are all closed, and none is diagnosis-matched to endometriosis or fibroids. A patient on Medicare with either diagnosis has no open fund to apply to today. See every program for this patient, with current status →

Sources: CMS ASP pricing files (Q4 2026); Medicare physician fee schedule (96372, national non-facility); Medicare Part B deductible (2026); Medicare Rights Center 2026 Medigap plan benefits chart; 37 commercial payer published price files (Q2 2026); AbbVie Copay Savings Card and myAbbVie Assist terms and status (public/programs-bundle.js, generated from the live programs corpus).

Reviewed September 20, 2026 by Erin Rose, CareCost Estimate founder. Methodology →